Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-PS: JTE-451 in Moderate to Severe Plaque Psoriasis
2018-003359-40Phase 2Completed
- Sponsor
- Akros Pharma Inc.
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing JTE-451 with Placebo (2 arms). Primary endpoint: Primary efficacy. Started Mar 2019; status: completed.
02
Drugs
JTE-451
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2018-003359-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003359-40.